Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab for Structural Progression in Psoriatic Arthritis
NCT03623867Phase 4Completed
- Sponsor
- The Chinese University of Hong Kong
- Start
- May 2020
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Secukinumab with Placebo (2 arms). Primary endpoint: Difference in changes in the volume of erosions on metacarpophalangeal joints (MCP) 2-4 at 48 weeks. Started May 2020; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT03623867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03623867.